Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA on ENHANCE

This article was originally published in The Tan Sheet

Executive Summary

The agency will review the recently completed study of the Merck/Schering-Plough combination cholesterol therapy Vytorin after it receives the final results, according to a Jan. 25 announcement. The study found "no statistically significant differences" between a group receiving the highest dose of Vytorin (10 mg ezetimibe plus 80 mg simvastatin) and a group receiving 80 mg simvastatin in either the primary endpoint or in key secondary imaging endpoints (1"The Tan Sheet" Jan. 21, 2008, p. 12). Investigators in the firms' ENHANCE trial determined the primary endpoint - mean change in the intima-media thickness - through ultrasound measurements of the carotid arteries. FDA said it is not clear why the lower levels of LDL cholesterol in patients who took Vytorin did not lead to lesser amounts of plaque, compared to patients treated with simvastatin alone...

You may also be interested in...



Merck, Schering-Plough resolve Vytorin investigation

Merck and Schering-Plough will pay $5.4 million to 35 states and the District of Columbia to resolve an investigation into the firms' delayed release of negative study results for the cholesterol-lowering drug Vytorin. The agreement, which is not an admission of liability, covers the states' and D.C.'s investigative costs. The ENHANCE trial found Vytorin was no more effective in reducing plaque in carotid arteries than simvastin (1"The Tan Sheet" Feb. 4, 2008)

ENHANCE Results Do Little To Enhance Merck’s Statin Product Outlook

The Merck/Schering-Plough combination cholesterol therapy Vytorin has failed to demonstrate significant benefit over simvastatin alone in preventing formation of arterial plaque in the ENHANCE trial

Keeping Track: Tumor-Agnostic Approval For Novartis; Submissions From Krystal, Menarini, And Astellas

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Topics

Latest News
UsernamePublicRestriction

Register

PS101320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel